scispace - formally typeset
Open AccessJournal ArticleDOI

Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium

TLDR
Results from the pooled analyses provide little evidence for an increased risk of lung cancer among habitual or long‐term cannabis smokers, although the possibility of potential adverse effect for heavy consumption cannot be excluded.
Abstract
To investigate the association between cannabis smoking and lung cancer risk, data on 2,159 lung cancer cases and 2,985 controls were pooled from 6 case-control studies in the US, Canada, UK, and New Zealand within the International Lung Cancer Consortium. Study-specific associations between cannabis smoking and lung cancer were estimated using unconditional logistic regression adjusting for sociodemographic factors, tobacco smoking status and pack-years; odds-ratio estimates were pooled using random effects models. Subgroup analyses were done for sex, histology and tobacco smoking status. The shapes of dose-response associations were examined using restricted cubic spline regression. The overall pooled OR for habitual versus nonhabitual or never users was 0.96 (95% CI: 0.66-1.38). Compared to nonhabitual or never users, the summary OR was 0.88 (95%CI: 0.63-1.24) for individuals who smoked 1 or more joint-equivalents of cannabis per day and 0.94 (95%CI: 0.67-1.32) for those consumed at least 10 joint-years. For adenocarcinoma cases the ORs were 1.73 (95%CI: 0.75-4.00) and 1.74 (95%CI: 0.85-3.55), respectively. However, no association was found for the squamous cell carcinoma based on small numbers. Weak associations between cannabis smoking and lung cancer were observed in never tobacco smokers. Spline modeling indicated a weak positive monotonic association between cumulative cannabis use and lung cancer, but precision was low at high exposure levels. Results from our pooled analyses provide little evidence for an increased risk of lung cancer among habitual or long-term cannabis smokers, although the possibility of potential adverse effect for heavy consumption cannot be excluded.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Medical Cannabis for the Primary Care Physician.

TL;DR: A case of a patient with several chronic health conditions who asks her primary care provider whether she should try medical cannabis is presented, providing a review of the pharmacology of medical cannabis, the state of evidence regarding the efficacy and variations in the types ofmedical cannabis, and safety monitoring considerations for the primary care physician.
Journal ArticleDOI

Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France.

TL;DR: Compared to smokers, non-smokers were significantly younger and more often females, and median overall survival was not statistically different between smokers and non- Smokers.
Journal ArticleDOI

Early Risk Factors for Daily Cannabis Use in Young Adults.

TL;DR: Children at risk of daily cannabis use as young adults can be identified early and benefit from early intervention to prevent problematic cannabis use, according to this longitudinal investigation of secondary schools in Montreal, Canada.
Journal ArticleDOI

[Cannabis and lung. What we know and everything we don't know yet].

TL;DR: La fumee de cannabis contient divers cannabinoides, comme le cannabidiol, qui possede aussi des proprietes anti-inflammatoires et antifibrotiques, avec ces proprietes puissent moduler en partie l’action deletere de the fumees de cannabis.
Journal ArticleDOI

Perioperative Cannabis as a Potential Solution for Reducing Opioid and Benzodiazepine Dependence

TL;DR: While cannabis likely has some therapeutic benefits, it must be treated as other medical controlled substances to truly elucidate its role in surgical patient care, and there are higher-quality data to support adjunctive use of cannabis for relief of pain, nausea, and insomnia.
References
More filters
Journal ArticleDOI

Measuring inconsistency in meta-analyses

TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Book

Cancer Epidemiology and Prevention

TL;DR: This is an account of cancer epidemiology has been expanded and contains new material on cancer biology, molecular epidemiology, preventive strategies and specific types and sites of cancer.

European Monitoring Centre for Drugs and Drug Addiction

Matt Anderson
TL;DR: The EMCDDA Programme 2, 'Analysis of responses', set out to identify how social reintegration is understood in each Member State and to map the availability of social reIntegration facilities in Member States according to these national perceptions.
Related Papers (5)